Shared Clavulanate and Tazobactam Antigenic Determinants Activate T-Cells from Hypersensitive Patients.
Journal
Chemical research in toxicology
ISSN: 1520-5010
Titre abrégé: Chem Res Toxicol
Pays: United States
ID NLM: 8807448
Informations de publication
Date de publication:
21 11 2022
21 11 2022
Historique:
pubmed:
23
9
2022
medline:
23
11
2022
entrez:
22
9
2022
Statut:
ppublish
Résumé
β-Lactamase inhibitors such as clavulanic acid and tazobactam were developed to overcome β-lactam antibiotic resistance. Hypersensitivity reactions to these drugs have not been studied in detail, and the antigenic determinants that activate T-cells have not been defined. The objectives of this study were to (i) characterize clavulanate- and tazobactam-responsive T-cells from hypersensitive patients, (ii) explore clavulanate and tazobactam T-cell crossreactivity, and (iii) define the antigenic determinants that contribute to T-cell reactivity. Antigen specificity, pathways of T-cell activation, and crossreactivity with clavulanate- and tazobactam-specific T-cell clones were assessed by proliferation and cytokine release assays. Antigenic determinants were analyzed by mass spectrometry-based proteomics methods. Clavulanate- and tazobactam-responsive CD4
Identifiants
pubmed: 36137197
doi: 10.1021/acs.chemrestox.2c00231
pmc: PMC9682523
doi:
Substances chimiques
Clavulanic Acid
23521W1S24
Tazobactam
SE10G96M8W
Epitopes
0
beta-Lactamase Inhibitors
0
Anti-Bacterial Agents
0
Aldehydes
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2122-2132Subventions
Organisme : Medical Research Council
ID : MR/L006758/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R009635/1
Pays : United Kingdom
Références
Antimicrob Agents Chemother. 2006 Jun;50(6):2244-7
pubmed: 16723596
Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):489-94
pubmed: 2560421
J Allergy Clin Immunol. 1995 Mar;95(3):748-50
pubmed: 7897159
Biochemistry. 1996 Sep 24;35(38):12421-32
pubmed: 8823177
Allergy. 2022 Oct;77(10):3070-3083
pubmed: 35611454
Int Arch Allergy Appl Immunol. 1988;85(2):184-9
pubmed: 3338858
Allergy. 2019 Sep;74(9):1817-1819
pubmed: 31034613
Front Immunol. 2021 Apr 13;12:630530
pubmed: 33927714
Biochemistry. 2001 Feb 13;40(6):1861-6
pubmed: 11327849
J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):694-702.e3
pubmed: 28342830
J Allergy Clin Immunol. 2007 Apr;119(4):973-81
pubmed: 17320939
Hepatology. 2015 Sep;62(3):887-99
pubmed: 25998949
Pharmacy (Basel). 2019 Jun 28;7(3):
pubmed: 31261671
J Allergy Clin Immunol. 2010 Jul;126(1):177-9
pubmed: 20434202
Lancet. 2019 Jan 12;393(10167):183-198
pubmed: 30558872
J Immunol. 2017 Jun 1;198(11):4217-4227
pubmed: 28438900
J Mol Biol. 1992 Apr 20;224(4):1103-13
pubmed: 1569569
J Antimicrob Chemother. 2003 Jul;52(1):18-23
pubmed: 12775671
Allergy. 2020 Jun;75(6):1300-1315
pubmed: 31749148
J Allergy Clin Immunol Pract. 2021 May;9(5):2001-2009
pubmed: 33444815
Allergy. 2015 Aug;70(8):1013-9
pubmed: 25913298
Gastroenterol Clin Biol. 1992;16(1):102-3
pubmed: 1537473
J Biol Chem. 2000 Sep 1;275(35):26674-82
pubmed: 10837472
J Allergy Clin Immunol. 2018 Jan;141(1):235-249.e8
pubmed: 28219704
Clin Microbiol Rev. 2010 Jan;23(1):160-201
pubmed: 20065329
Chem Res Toxicol. 2016 Oct 17;29(10):1762-1772
pubmed: 27603302
Allergol Int. 2015 Jul;64(3):280-1
pubmed: 26117262
J Allergy Clin Immunol. 2010 Feb;125(2):502-505.e2
pubmed: 20159266
Allergy. 2020 Oct;75(10):2562-2573
pubmed: 32246774
Expert Rev Anti Infect Ther. 2019 Jun;17(6):429-435
pubmed: 31067139
Clin Exp Allergy. 2002 Nov;32(11):1644-50
pubmed: 12569987
Clin Exp Allergy. 2016 Feb;46(2):264-74
pubmed: 26662186
J Investig Allergol Clin Immunol. 2012;22(5):363-71
pubmed: 23101312
Int Arch Allergy Appl Immunol. 1985;76(1):42-6
pubmed: 2578436
J Immunol. 1995 Jul 1;155(1):462-72
pubmed: 7602118
J Immunol. 2011 Jul 1;187(1):200-11
pubmed: 21606251